Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer

BMC Research Notes

Volumn 7, Issue 1, 2014, Pages

  Takahashi, Naoki ^a   Yamada, Yasuhide ^a   Taniguchi, Hirokazu ^a   Fukahori, Masaru ^a   Sasaki, Yusuke ^a   Shoji, Hirokazu ^a   Honma, Yoshitaka ^a   Iwasa, Satoru ^a   Takashima, Atsuo ^a   Kato, Ken ^a   Hamaguchi, Tetsuya ^a   Shimada, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; RAS PROTEIN;

CANCER STAGING; COHORT ANALYSIS; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; STOMACH TUMOR;

COHORT STUDIES; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; STOMACH NEOPLASMS;

EID: 84900437949     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-7-271     Document Type: Article

References (29)

1. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 69 10.3322/caac.20107 21296855
2. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A, Lancet Oncol 2009 10 1063 1069 10.1016/S1470-2045(09)70259-1 19818685
3. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M, Lancet Oncol 2008 9 215 221 10.1016/S1470-2045(08)70035-4 18282805
4. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI, Ann Oncol 2009 20 666 673 10.1093/annonc/mdn717 19153121
5. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK, Lancet 2010 376 687 697 10.1016/S0140-6736(10)61121-X 20728210
6. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. Van Cutsem E, De Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, Peng Yong W, Langer B, Delmar P, Scherer SJ, Shah MA, J Clin Oncol 2012 30 2119 2127 10.1200/JCO.2011.39.9824 22565005
7. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt C, Barbachano Y, Lancet Oncol 2013 34 481 489
8. Advances in targeting the RAS/RAF/MEK/ErK mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Friday BB, Adjei AA, Clin Cancer Res 2008 14 342 346 10.1158/1078-0432.CCR-07-4790 18223206 (Pubitemid 351226098)
9. BRAF and RAS mutations in human lung cancer and melanoma. Brose MS, Volpe P, Feldman M, Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL, Cancer Res 2002 62 6997 7000 12460918 (Pubitemid 35424092)
10. BRAF mutation in thyroid cancer. Xing M, Endocr Relat Cancer 2005 12 245 262 10.1677/erc.1.0978 15947100 (Pubitemid 40896444)
11. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan Fleuren G, Houmadi R, Diss T, Warren B, Al Adnani M, de Goeij AP, Krausz T, Flanagan AM, The Cancer Genome Project, J Pathol 2004 202 336 340 10.1002/path.1521 14991899 (Pubitemid 38325243)
12. High frequency of mutations of the PIK3CA gene in human cancers. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE, Science 2004 304 554 10.1126/science.1096502 15016963 (Pubitemid 38541907)
13. Helical domain and kinase domain mutations in p110 alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Zhao L, Vogt PK, Proc Natl Acad Sci U S A 2008 105 2652 2657 10.1073/pnas.0712169105 18268322 (Pubitemid 351520568)
14. BRAF and KRAS mutations in stomach cancer. Lee SH, Lee JW, Soung YH, Kim HS, Park WS, Kim SY, Lee JH, Park JY, Cho YG, Kim CJ, Nam SW, Kim SH, Lee JY, Yoo NJ, Oncogene 2003 22 6942 6945 10.1038/sj.onc.1206749 14534542 (Pubitemid 37386695)
15. Mutations of BRAF and KRAS in gastric cancerand their association with microsatellite instability. Zhao W, Chan TL, Chu KM, Chan AS, Stratton MR, Yuen ST, Leung SY, Int J Cancer 2004 108 167 169 10.1002/ijc.11553 14618633 (Pubitemid 37444461)
16. Mutations of PIK3CA in gastric adenocarcinoma. Li VS, Wong CW, Chan TL, Chan AS, Zhao W, Chu KM, So S, Chen X, Yuen ST, Leung SY, BMC Cancer 2005 5 29 10.1186/1471-2407-5-29 15784156 (Pubitemid 41461099)
17. Impact of vascular endothelial growth factor1, 2and 3 expression on the outcome of patients with gastric cancer. Hirashima Y, Yamada Y, Matsubara J, Takahari D, Okita N, Takashima A, Kato K, Hamaguchi T, Shirao K, Shimada Y, Taniguchi H, Shimoda T, Cancer Sci 2009 100 310 315 10.1111/j.1349-7006.2008. 01020.x 19068081
18. Phase II study of cetuximab in combination with cisplatin anddocetaxel in patients with untreated advanced gastric orgastro-oesophageal junction adenocarcinoma (DOCETUX study). Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Cascinu S, Rojas Llimpe FL, Stella G, Schinzari G, Artale S, Mutri V, Giaquinta S, Giannetta L, Bardelli A, Martoni AA, Br J Cancer 2009 101 1261 1268 10.1038/sj.bjc.6605319 19773760
19. Cetuximab plusoxaliplatin/leucovorin/5-fluorouracil inmetastatic gastric cancer: a phase II study of theArbeitsgemeinschaftInternistischeOnkologie (AIO). Lordick F, Luber B, Lorenzen S, Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, Endlicher E, Röthling N, Schuster T, Keller G, Fend F, Peschel C, Br J Cancer 2010 102 500 505 10.1038/sj.bjc.6605521 20068568
20. Cetuximab with irinotecan, folinic acid and5-fluorouracil as first-line treatment in advancedgastroesophageal cancer: a prospective multi- centerbiomarker-oriented phase II study. Moehler M, Mueller A, Trarbach T, Lordick F, Seufferlein T, Kubicka S, Geissler M, Schwarz S, Galle PR, Kanzler S, German Arbeitsgemeinschaft Internistische Onkologie, Ann Oncol 2011 22 1358 1366 10.1093/annonc/mdq591 21119032
21. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH, Oncogene 2005 24 1477 1480 10.1038/sj.onc.1208304 15608678 (Pubitemid 40343128)
22. Mutation of the PIK3CA oncogene in human cancers. Karakas B, Bachman KE, Park BH, Br J Cancer 2006 94 455 459 10.1038/sj.bjc.6602970 16449998 (Pubitemid 43289745)
23. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Mao C, Yang ZY, Hu XF, Chen Q, Tang JL, Ann Oncol 2012 23 1518 1525 10.1093/annonc/mdr464 22039088
24. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Catasus L, Gallardo A, Cuatrecasas M, Jaime P, Mod Pathol 2008 21 131 139 18084252 (Pubitemid 351172164)
25. PIK3CA mutation associates with improved outcome in breast cancer. Kalinsky K, Jacks LM, Heguy A, Patil S, Prat J, Clin Cancer Res 2009 15 5049 5059 10.1158/1078-0432.CCR-09-0632 19671852
26. Novel therapeutic targets in non-small cell lung cancer. Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ, Kurzrock R, J Thorac Oncol 2011 6 1601 1612 10.1097/JTO.0b013e31822944b3 21849857
27. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, Lazar AJ, Hwu P, Davies MA, Cancer 2012 118 4014 4023 10.1002/cncr.26724 22180178
28. Prognostic significance of NRAS gene mutations in children with acute myelogenous leukemia. Aly RM, El-Sharnoby MR, Hagag AA, Mediterr J Hematol Infect Dis 2011 3 2011055 22220252
29. Effects of KRAS, BRAF, NRAS and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy -refractory metastatic colorectal cancer: a retrospective consortium analysis. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, et al. Lancet Oncol 2010 11 753 762 10.1016/S1470-2045(10)70130-3 20619739